Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Income from Continuing Operations: 2014-2024

Historic Income from Continuing Operations for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to -$110.0 million.

  • Viking Therapeutics' Income from Continuing Operations fell 262.79% to -$90.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$237.3 million, marking a year-over-year decrease of 139.32%. This contributed to the annual value of -$110.0 million for FY2024, which is 28.17% down from last year.
  • Viking Therapeutics' Income from Continuing Operations amounted to -$110.0 million in FY2024, which was down 28.17% from -$85.8 million recorded in FY2023.
  • Viking Therapeutics' 5-year Income from Continuing Operations high stood at -$39.4 million for FY2020, and its period low was -$110.0 million during FY2024.
  • In the last 3 years, Viking Therapeutics' Income from Continuing Operations had a median value of -$85.8 million in 2023 and averaged -$88.2 million.
  • Data for Viking Therapeutics' Income from Continuing Operations shows a maximum YoY plummeted of 53.80% (in 2020) over the last 5 years.
  • Over the past 5 years, Viking Therapeutics' Income from Continuing Operations (Yearly) stood at -$39.4 million in 2020, then crashed by 39.44% to -$55.0 million in 2021, then declined by 25.08% to -$68.8 million in 2022, then decreased by 24.78% to -$85.8 million in 2023, then dropped by 28.17% to -$110.0 million in 2024.